ERBB2 is altered in 11.17% of endometrial serous adenocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH1 is altered in 1.42% of endometrial serous adenocarcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 1.04% of endometrial serous adenocarcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 1.43% of endometrial serous adenocarcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 1.1% of endometrial serous adenocarcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 1.14% of endometrial serous adenocarcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 88.0% of endometrial serous adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for endometrial serous adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].